JP2018534243A5 - - Google Patents

Download PDF

Info

Publication number
JP2018534243A5
JP2018534243A5 JP2018511611A JP2018511611A JP2018534243A5 JP 2018534243 A5 JP2018534243 A5 JP 2018534243A5 JP 2018511611 A JP2018511611 A JP 2018511611A JP 2018511611 A JP2018511611 A JP 2018511611A JP 2018534243 A5 JP2018534243 A5 JP 2018534243A5
Authority
JP
Japan
Prior art keywords
pyrv
refers
isomer
compound
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018511611A
Other languages
English (en)
Japanese (ja)
Other versions
JP6933644B2 (ja
JP2018534243A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/050270 external-priority patent/WO2017041040A1/en
Publication of JP2018534243A publication Critical patent/JP2018534243A/ja
Publication of JP2018534243A5 publication Critical patent/JP2018534243A5/ja
Application granted granted Critical
Publication of JP6933644B2 publication Critical patent/JP6933644B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018511611A 2015-09-04 2016-09-02 アンドロゲン受容体拮抗薬 Expired - Fee Related JP6933644B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562214613P 2015-09-04 2015-09-04
US62/214,613 2015-09-04
PCT/US2016/050270 WO2017041040A1 (en) 2015-09-04 2016-09-02 Androgen receptor antagonists

Publications (3)

Publication Number Publication Date
JP2018534243A JP2018534243A (ja) 2018-11-22
JP2018534243A5 true JP2018534243A5 (enExample) 2019-12-12
JP6933644B2 JP6933644B2 (ja) 2021-09-08

Family

ID=58188655

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018511611A Expired - Fee Related JP6933644B2 (ja) 2015-09-04 2016-09-02 アンドロゲン受容体拮抗薬

Country Status (5)

Country Link
US (1) US10428048B2 (enExample)
EP (1) EP3350167A4 (enExample)
JP (1) JP6933644B2 (enExample)
CN (1) CN108349900A (enExample)
WO (1) WO2017041040A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
WO2019023651A2 (en) 2017-07-28 2019-01-31 Massachusetts Institute Of Technology MODULATORS OF THE SMALL MOLECULE ANDROGEN RECEPTOR
EP3664783A1 (en) * 2017-08-09 2020-06-17 Nangenex Nanotechnology Incorporated Pharmaceutical composition comprising abiraterone acetate and darulotamide
KR20220163435A (ko) * 2020-04-02 2022-12-09 유니버시티 오브 테네시 리서치 파운데이션 피라졸릴프로판아미드 화합물 및 전립선암의 치료에서의 그 용도
EP4023649A1 (en) 2020-12-30 2022-07-06 Industrial Technology Research Institute Androgen receptor binding bifunctional molecules

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH509382A (it) 1967-06-23 1971-06-30 Crc Ricerca Chim Metodo per l'ottenimento dei colori pirolchinolici e dei loro sali derivati
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
WO2006078754A1 (en) * 2005-01-18 2006-07-27 Immusol Incorporated Novel quinolinium salts and derivatives
CN101106992A (zh) * 2005-01-18 2008-01-16 伊姆索公司 新颖的喹啉鎓盐和衍生物
WO2008128100A1 (en) 2007-04-13 2008-10-23 The Regents Of The University Of California Small-molecule inhibitors of the androgen receptor
JP5599385B2 (ja) 2008-04-24 2014-10-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アンドロゲンレセプターの小分子阻害剤
KR102193461B1 (ko) * 2014-04-24 2020-12-21 동아에스티 주식회사 퀴놀린계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제

Similar Documents

Publication Publication Date Title
JP2018534243A5 (enExample)
JP2015063536A5 (enExample)
JP2016537346A5 (enExample)
CL2008001898A1 (es) Compuestos derivados de pirazinona, inhibidores de p38; proceso de preparacion de estos; composicion farmaceutica que los comprende; combinacion farmaceutica que los comprende; uso para tratar enferemedades pulmonares obstructivas cronicas y asma.
JP2016510323A5 (enExample)
JP2015532645A5 (enExample)
JP2013063963A5 (ja) 複素環化合物
DK2158185T3 (da) Fremgangsmåde til fremstilling af difluormethylsubstituerede pyrazolforbindelser
JP2016505614A5 (enExample)
JP2016531126A5 (enExample)
JP2014043437A5 (ja) 有機化合物
MX377644B (es) 6.7.beta-epóxidos esteroideos como intermedios químicos.
MX2018014164A (es) Intermedios para la sintesis de derivados de acido biliar, en particular, de acido obeticolico.
JP2020502116A5 (enExample)
WO2021111462A1 (en) An improved process for the preparation of osimertinib mesylate
RU2016148821A (ru) Способ радиомечения
JP2019523279A5 (enExample)
CN102850282A (zh) 3-烷氧基取代-2-吡嗪甲酰氨类化合物及其用途
JP2017511361A5 (enExample)
WO2016110798A1 (en) An improved process for the preparation of lurasidone and its intermediate
CN111247160A (zh) 一种胆酸类化合物的制备方法
CN106008506B (zh) 取代嘌呤类衍生物及其制备方法与应用
Sheibani Regioselective combination of 1, 3-dinucleophiles such as 2-mercaptobenzimidazole, 5-mercapto-3-phenyltriazole and potassium thiocyanate with 2, 2-dicyanooxiranes
JP2017095442A5 (enExample)
WO2016078107A1 (zh) 一种哌嗪类药物中间体的合成方法